



SIGACHI LABORATORIES LIMITED

Corporate Office: 402, Raghava Ratna Towers,
Chirag Ali Lane, Hyderabad - 500 001. (INDIA)
Ph. : 040-23204230, 23204273 E-mail: sigachilaboratories@yahoo.co.in
CIN: L24230TG1994PLC018786 GSTIN: 36AACCS8220M1Z4

Date: 14.02.2020

Head Listing & Compliance
Metropolitan Stock Exchange of India Limited
Vibgyor Towers, 4th Floor
Plot No.62, G- Block, Opp Trident Hotel,
Bandra Kurla Complex, Bandra (E)
Mumbai — 400 098

Dear Sir,

Sub: Outcome of the Board Meeting held today i.e., on 14th February, 2020 – Submission of Un audited financial results for the quarter and nine months ended 31st December, 2019- Reg.

Pursuant to Regulation 33 and Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors at its Meeting held today i.e. Friday, 14th February, 2020 has inter-alia considered and approved the Unaudited Financial Results for the quarter and nine months ended 31st December, 2019. The Unaudited Financial Results for the quarter and nine months ended 31st December, 2019 along with Limited Review Report of the Statutory Auditors are enclosed herewith.

This is for your information and record.

Thanking you,

Yours faithfully,

For Sigachi Laboratories Limited


(Boina Kumar)
Chief Financial Officer



Meeting Commenced at 04.00 P.M.
Meeting Concluded at 05.30 P.M.

SIGACHIL LABORATORIES LIMITED
 Regd. Office: S.No: 530 & 534, Bonthapally - 502 313, Gunmadidala Mandal, Sanga Reddy District, Telangana.
 Tel No.: 040 - 23204230 / 23204273.

Website: www.sillab.com, Email: sigachilaboratories@yahoo.co.in
 CIN: L24230TG1994PLC018786

Statement of Un-Audited Financial Results For The Quarter and Nine Months Ended 31st December, 2019

(Rs. In Lakhs)

Sl.No	Particulars	Quarter ended				Nine Months Ended		Year ended 31.03.2019
		31.12.2019 Un Audited	30.09.2019 Un Audited	31.12.2018 Un Audited	31.12.2019 Un Audited	31.12.2018 Un Audited	Audited	
1	Revenue from Operations	54.60	29.98	48.71	111.56	108.05	169.55	
2	Other Income	25.77	17.51	9.05	93.58	17.99	28.23	
3	Total Income (1+2)	80.37	47.49	57.76	205.14	126.04	197.78	
4	Expenses	-	-	-	-	-	-	
	a) Cost of Materials consumed	-	-	-	-	-	-	
	b) Purchase of Stock-in-Trade	-	-	-	-	-	-	
	c) Change in Inventories	-	-	-	-	-	-	
	d) Employee benefits expense	5.87	5.79	6.05	21.07	18.03	34.83	
	e) Finance costs	-	-	-	-	-	-	
	f) Depreciation and amortization expense	4.14	3.56	3.60	11.27	11.22	14.72	
	g) Other expenses	2.23	3.39	2.38	9.18	9.71	20.83	
	Total expenses	12.24	12.74	12.03	41.52	38.96	70.38	
5	Profit/(loss) before exceptional and extraordinary items and tax (3-4)	68.13	34.75	45.73	163.62	87.08	127.40	
6	Exceptional Items	-	-	-	-	-	-	
7	Profit/(loss) before extraordinary items and tax (5-6)	68.13	34.75	45.73	163.62	87.08	127.40	
8	Extraordinary items	-	-	-	-	-	-	
9	Profit/(Loss) before tax (7-8)	68.13	34.75	45.73	163.62	87.08	127.40	
10	Tax expense	-	-	-	-	-	-	
	(a) Current tax	12.00	6.75	5.50	24.00	15.75	26.61	
	(b) Deferred tax	1.44	0.14	0.32	1.71	1.01	(3.72)	
	Total Tax Expense	13.44	6.89	5.82	25.71	16.76	22.89	
11	Profit/(Loss) for the Period (9-10)	54.69	27.86	39.91	137.91	70.32	104.51	
12	Other Comprehensive Income (OCI)	26.94	(12.05)	15.94	0.97	(2.13)	45.01	
	(a) Items that will not be reclassified to profit or loss	-	-	-	-	-	-	
	(b) Items that will be reclassified to profit or loss	26.94	(12.05)	15.94	0.97	(2.13)	45.01	
	Total Other Comprehensive Income	26.94	(12.05)	15.94	0.97	(2.13)	45.01	
	Total Comprehensive Income (11+12)	81.63	15.81	55.85	138.88	68.19	149.52	
13	Paid-up Equity Share Capital (Face Value Rs. 10/- per share)	675.31	675.31	675.31	675.31	675.31	675.31	
14	Other Equity	-	-	-	-	-	-	
15	Earnings per equity share (of Rs. 10/- each) (not annualized) (Rs.)							
	(1) Basic	0.81	0.41	0.59	2.04	1.04	1.55	
	(2) Diluted	0.81	0.41	0.59	2.04	1.04	1.55	

Segment wise Revenue, Results and Capital Employed for the Quarter and Nine Months Ended 31st December, 2019

(Rs. in Lakhs)

Sl.No	Particulars	Quarter ended		Nine Months Ended		Year ended	
		31.12.2019 Un Audited	30.09.2019 Un Audited	31.12.2018 Un Audited	31.12.2019 Un Audited	31.12.2018 Un Audited	31.03.2019 Audited
1	Segment Revenue						
	a) Bulk Drugs and Intermediates (Lease Rents)	27.50	27.00	26.00	72.50	68.50	104.50
	b) Investments	52.87	20.49	31.76	132.64	57.54	93.28
	Total	80.37	47.49	57.76	205.14	126.04	197.78
	Less: Inter Segment Revenue	-	-	-	-	-	-
	Net sales/Income from Operations	80.37	47.49	57.76	205.14	126.04	197.78
2	Segment Results Profit/(Loss) before tax and finance Costs from each segment						
	a) Bulk Drugs and Intermediates (Lease Rents)	23.21	23.51	22.13	60.15	56.12	88.10
	b) Investments	52.87	20.49	31.76	132.64	57.54	93.28
	Total	76.08	44.00	53.89	192.79	113.66	181.38
	Less: (i) Finance Costs	-	-	-	-	-	-
	(ii) Other Un-allocable Expenditure net off	7.95	9.25	8.16	29.17	26.58	53.98
	(iii) Un-allocable income	-	-	-	-	-	-
	Total Profit Before Tax	68.13	34.75	45.73	163.62	87.08	127.40
3	Capital Employed						
	(Segment Assets – Segment Liabilities)						
	a) Bulk Drugs and Intermediates	568.68	493.85	337.71	568.68	337.71	490.28
	b) Investments	1,713.88	1,702.92	1,711.27	1,713.88	1,711.27	1,649.26
	Total	2,282.56	2,196.77	2,048.98	2,282.56	2,048.98	2,139.54

Notes :

- The above Financial results have been reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their respective Meetings held on 14th February, 2020.
- The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- Previous year / period figures have been recasted / regrouped / reclassified wherever necessary to make them comparable with current year / period figures.

For SIGACHI LABORATORIES LIMITED

for SIGACHI LABORATORIES LIMITED

By Order of the Board

Sd/-

(T.R.Sekhar)

Executive Director

DIN:02943146

Place : Hyderabad
Date : 14.02.2020


Chief Financial Officer

Attested

INDEPENDENT AUDITORS' REVIEW REPORT

To
The Board of Directors,
Sigachi Laboratories Limited

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **Sigachi Laboratories Limited** ("the company") for the quarter and Nine months ended 31st December, 2019 ("the statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No.CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
2. We conducted our review of the statement in accordance with Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review is limited primarily to enquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
3. Based on our review conducted as stated above nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the applicable Indian Accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Niranjn & Narayan
Chartered Accountants

FRN: 005899S



M. Niranjn

M. Niranjn

Partner-Memb No. 029552

UDIN: 20029552AAAACG4825

Date: 14.02.2020

Place: Hyderabad